Munich - Delayed Quote EUR

Bio-Rad Laboratories Inc (BUWA.MU)

220.00

+2.00

+(0.92%)

At close: April 25 at 8:17:20 AM GMT+2

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 2 days ago

BIO-B
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technologyLOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research’s

GlobeNewswire 3 days ago

BIO

BIO-B

BDSX
Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?

Ariel Investments, an investment management company, released its “Ariel Appreciation Fund” first-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, investors fled to shelter as hopes for another year of U.S. outperformance, driven by economic momentum and the new administration’s pro-business approach swiftly gave way to tariff fears […]

Insider Monkey 4 days ago

BIO-B
Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned -5.14% in the first quarter, compared to the S&P 500’s -4.27% return and Russell 1000 Value’s 2.14% return. The firm’s stock price performance was volatile, but its confidence […]

Insider Monkey 5 days ago

BIO-B
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

HERCULES, Calif., April 15, 2025--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2025 on Thursday, May 1, 2025, following the close of the market. Management will discuss these results in a conference call scheduled for 2:30 PM Pacific Time (5:30 PM Eastern Time) that day.

Business Wire 10 days ago

BIO

BIO-B
Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

Simply Wall St. 22 days ago

BIO

BIO-B
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.

Zacks 23 days ago

BIO-B

BSX
Bio-Techne Opens New Customer Experience Centre in Germany

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Zacks 26 days ago

TECH

QGEN

BIO-B
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.

Zacks 26 days ago

CRL

TMO

BIO-B
Alger Russell Innovation Index Updates for First Quarter 2025

Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, March 21, 2025, the Index will be rebalanced, and the following changes will be effective.

PR Newswire last month

HPE

PYPL

RBLX
Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Key Insights Significantly high institutional ownership implies Bio-Rad Laboratories' stock price is sensitive to their...

Simply Wall St. last month

BIO

BIO-B
Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

We recently compiled a list of the 7 Best Medical Technology Stocks To Buy According To Analysts. In this article, we are going to take a look at where Bio-Rad Laboratories, Inc. (NYSE:BIO) stands against the other medical technology stocks. Growth and Drivers of the Global MedTech Market The MedTech sector is crucial in healthcare, which […]

Insider Monkey last month

BIO-B
Bio-Rad (BIO) International Revenue Performance Explored

Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks last month

BIO-B
HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Henry Schein's fourth-quarter results reflect stable dental and medical end-markets.

Zacks last month

HSIC

CAH

BIO-B
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks last month

VCYT

CAH

RMD
Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

GMED's fourth-quarter 2024 performance reflects strong synergies from the NuVasive merger.

Zacks 2 months ago

GMED

RMD

CAH
EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Exact Sciences' fourth-quarter 2024 performance benefits from the robust momentum in Cologuard adoption.

Zacks 2 months ago

EXAS

RMD

CAH
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024.

Zacks 2 months ago

PEN

RMD

CAH
Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

MDT delivers strong earnings in the fiscal 2025 third quarter, with significant improvements in both gross and operating margins.

Zacks 2 months ago

MDT

RMD

CAH
BIO Stock Might Rise Following the Offer to Acquire Stilla

Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.

Zacks 2 months ago

BIO-B

RMD

Performance Overview

Return	BUWA.MU	S&P 500 (^GSPC)
YTD	-30.97%	-6.06%
1-Year	-15.74%	+9.44%
3-Year	-56.37%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Bio-Rad Laboratories Inc (BUWA.MU)

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?

Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Bio-Techne Opens New Customer Experience Centre in Germany

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Bio-Rad (BIO) International Revenue Performance Explored

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Performance Overview